Exploring the Mechanisms of Resveratrol in ARDS Treatment: From Network Pharmacology and Molecular Docking to In Vitro Validation
Chemical Biology & Drug Design · 2025
DOI: 10.1111/cbdd.70187 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2025. Verfasst von Zhili Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Basic and Clinical Key Laboratory of Cardiovascular and Cerebrovascular Diseases, Bengbu Medical University, Bengbu, China. Hauptthemen laut MEDLINE: Resveratrol, Molecular Docking Simulation, Respiratory Distress Syndrome. Die Arbeit nennt 61 Literaturangaben. Gefördert von: the Natural Science Foundation of Anhui Province, the Natural Science Foundation of the Education Department of Anhui Province, 512 Talent Cultivation Plan of Bengbu Medical College.
Abstract (Originalsprache)
Acute respiratory distress syndrome (ARDS) is a severe and critical clinical pulmonary disease. Resveratrol (RES), a non‐flavonoid polyphenolic compound, has shown potential therapeutic effects. However, the underlying mechanism of RES treatment for ARDS remains unclear. This study employed network pharmacology to predict potential targets and metabolic pathways involved in RES treatment for ARDS. Molecular docking and experimental validation were performed to confirm key targets and metabolic pathways. A comprehensive database search identified 115 RES‐ARDS‐related targets. Subsequently, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses highlighted the JAK/STAT pathway, which was further investigated with RES in the treatment of ARDS. Hematoxylin–eosin (HE) staining visualized lung damage. Western blot analysis showed that RES significantly downregulated p‐JAK2, NLRP3, IL‐18, and p‐STAT3 expression ( p < 0.05). A variety of animal experiments have substantiated that RES can effectively inhibit inflammation and oxidative stress, and promote blood barrier repair. In conclusion, this study provides new insights into the protective mechanism of RES against ARDS, highlighting its potential as a therapeutic agent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Basic and Clinical Key Laboratory of Cardiovascular and Cerebrovascular Diseases, Bengbu Medical University, Bengbu, China.
- Department of Physiology, School of Basic Medicine, Bengbu Medical University, Bengbu, China.
ORCID-Profile: Wanting Hu, Ying Yu
Förderung
- the Natural Science Foundation of Anhui Province
- the Natural Science Foundation of the Education Department of Anhui Province
- 512 Talent Cultivation Plan of Bengbu Medical College
- National College Students Innovation and Entrepreneurship Training Program
- Natural Science Foundation of Anhui Province
Zitieren
APA
Zhang, Z., Hu, W., Cong, X., Zhang, J., Sun, S., Qin, M., Zhang, W., & Yu, Y. (2025). Exploring the Mechanisms of Resveratrol in ARDS Treatment: From Network Pharmacology and Molecular Docking to In Vitro Validation. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70187
Vancouver
Zhang Z, Hu W, Cong X, Zhang J, Sun S, Qin M, et al. Exploring the Mechanisms of Resveratrol in ARDS Treatment: From Network Pharmacology and Molecular Docking to In Vitro Validation. Chemical Biology & Drug Design. 2025. doi:10.1111/cbdd.70187
BibTeX
@article{Zhang2025,
author = {Zhang, Zhili and Hu, Wanting and Cong, Xixi and Zhang, Junjie and Sun, Siyu and Qin, Meng and Zhang, Weiping and Yu, Ying},
title = {Exploring the Mechanisms of Resveratrol in ARDS Treatment: From Network Pharmacology and Molecular Docking to In Vitro Validation},
journal = {Chemical Biology & Drug Design},
year = {2025},
doi = {10.1111/cbdd.70187}
}
EUVIMED